News und Analysen
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine
Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer
Ipsen (Euronext: IPN; ADR: IPSEY), today announced the primary analysis of the Phase I/II study evaluating the investigational use of irinotecan liposome injection (Onivyde®) in combination with
Lantheus Holdings to Showcase the Potential of PyL™ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture
Novocure to Report Second Quarter 2020 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management
Lysogene Announces a Research Collaboration With the Weizmann Institute of Science
Regulatory News:
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced that the company has entered
Premier Inc. Calls for National Stockpiling Standards to Prevent Redundant Efforts, Next Wave of Product Shortages
Nearly 90 percent of healthcare providers are contributing to stockpiles of critical medical supplies and drugs intended to last as long as 90 days, according to a recent survey conducted by
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to
Dexcom Schedules Second Quarter 2020 Earnings Release and Conference Call for July 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2020 financial results after market close on Tuesday, July 28, 2020. Management will hold a conference call to
LivaNova to Host Conference Call for Second Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m
Pfizer Declares Third-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of
Pfizer Declares Third-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of
Bayer: Darum bricht die Aktie heute so stark ein!
Gestern gab es gleich zwei positive Nachrichten des Leverkusener Bayer-Konzerns (WKN: BAY001), die sich jedoch erst heute auf den Aktienkurs auswirken konnten. Denn leider kamen die News erst nach
Bayer: Darum bricht die Aktie heute so stark ein!
Gestern gab es gleich zwei positive Nachrichten des Leverkusener Bayer-Konzerns (WKN: BAY001), die sich jedoch erst heute auf den Aktienkurs auswirken konnten. Denn leider kamen die News erst nach
Premier Inc. Survey: Alternate Site Providers Report Increased PPE Needs but Face Challenges with Traditional Distribution Channels
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released survey results finding that the majority of alternate site providers, including senior living facilities
Sangamo Announces R&D Organization Changes
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.
Going forward, research and development will each be managed as separate functions
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private
Waters Extends the Capability and Power of its High-Resolution Mass Spectrometers
Waters Corporation (NYSE:WAT) announced today a new fragmentation technique and an imaging option for its high-resolution mass spectrometers giving research scientists working across a broad range
Waters Introduces the New Arc High-Performance Liquid Chromatograph to Help Laboratories Meet Quality and Production Targets
Waters Corporation (NYSE:WAT) today introduced the Waters™ Arc™ HPLC System, a new high-performance liquid chromatograph (HPLC) for routine testing in the pharmaceutical, food, academic and
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
Illumina, Inc. (NASDAQ:ILMN) has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs
Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced the
Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (OMXS